2025 연구자 정보 (3 / 654)
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| Author Name | 제1저자 여부 | 교신저자 여부 | Address | ResearcherID | ORCID | Paper Title | WoS Edition | 최상위 JCR(%) | WoS Category | Related Email |
|---|---|---|---|---|---|---|---|---|---|---|
|
Qin, Shukui (Qin, SK) |
Jinling Hosp, Canc Ctr Nanjing, Nanjing, Peoples R China |
|
|
[JCR상위 0.2%] Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study | SCIE | 0.2 | MEDICINE, GENERAL & INTERNAL | bsangro@unav.es | ||
|
Ramchandren, Sindhu (Ramchandren, S) |
교신저자 | Janssen Res & Dev, Titusville, NJ 08560 USA |
D-6942-2012 Ramchandren, Sindhu |
|
[JCR상위 0.2%] Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised double-blind, placebo-controlled study | SCIE | 0.2 | CLINICAL NEUROLOGY | sramcha4@its.jnj.com | |
|
Ren, Zhenggang (Ren, ZG) |
Fudan Univ, Zhongshan Hosp, Liver Canc Inst, Dept Hepat Oncol, Shanghai, Peoples R China |
|
|
[JCR상위 0.2%] Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study | SCIE | 0.2 | MEDICINE, GENERAL & INTERNAL | bsangro@unav.es | ||
|
Sanga, Panna (Sanga, P) |
Janssen Res & Dev, Titusville, NJ 08560 USA |
|
|
[JCR상위 0.2%] Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised double-blind, placebo-controlled study | SCIE | 0.2 | CLINICAL NEUROLOGY | sramcha4@its.jnj.com | ||
|
Sangro, Bruno (Sangro, B) |
제1저자 | 교신저자 |
Clin Univ Navarra, Liver Unit, Pamplona 31008, Spain Clin Univ Navarra, HPB Oncol Area, Pamplona 31008, Spain CIBEREHD, Pamplona 31008, Spain |
AFW-4106-2022 Sangro, Bruno |
|
[JCR상위 0.2%] Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study | SCIE | 0.2 | MEDICINE, GENERAL & INTERNAL | bsangro@unav.es |
|
Santos, Florinda A. (Santos, FA) |
Barretos Canc Hosp, Dept Oncol, Barretos, Brazil |
|
|
[JCR상위 0.2%] Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study | SCIE | 0.2 | MEDICINE, GENERAL & INTERNAL | bsangro@unav.es | ||
|
Sevilla, Teresa (Sevilla, T) |
Hosp Univ & Politecn, Dept Hematol & Med Oncol, Valencia, Spain IIS La Fe, Valencia, Spain Univ Valencia, Valencia, Spain |
|
|
[JCR상위 0.2%] Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised double-blind, placebo-controlled study | SCIE | 0.2 | CLINICAL NEUROLOGY | sramcha4@its.jnj.com | ||
|
Sheehan, John J. (Sheehan, JJ) |
Janssen Global Serv, Global Med Affairs, Raritan, NJ USA |
|
|
[JCR상위 0.2%] Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised double-blind, placebo-controlled study | SCIE | 0.2 | CLINICAL NEUROLOGY | sramcha4@its.jnj.com | ||
|
Sivakumar, Kumaraswamy (Sivakumar, K) |
Neuromuscular Res Ctr, Phoenix, AZ 85028 USA Neuromuscular Clin Arizona, Phoenix, AZ USA |
|
|
[JCR상위 0.2%] Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised double-blind, placebo-controlled study | SCIE | 0.2 | CLINICAL NEUROLOGY | sramcha4@its.jnj.com | ||
|
Smilowski, Marek (Smilowski, M) |
Upper Silesian Med Ctr, Katowice, Poland |
|
|
[JCR상위 0.2%] Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised double-blind, placebo-controlled study | SCIE | 0.2 | CLINICAL NEUROLOGY | sramcha4@its.jnj.com | ||
|
Sun, Hong (Sun, H) |
Janssen Res & Dev, Titusville, NJ 08560 USA |
|
|
[JCR상위 0.2%] Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised double-blind, placebo-controlled study | SCIE | 0.2 | CLINICAL NEUROLOGY | sramcha4@its.jnj.com | ||
|
Suttichaimongkol, Tanita (Suttichaimongkol, T) |
Khon Kaen Univ, Fac Med, Dept Med, Div Gastroenterol & Hepatol, Khon Kaen, Thailand |
JDW-6886-2023 Suttichaimongkol, Tanita |
|
[JCR상위 0.2%] Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study | SCIE | 0.2 | MEDICINE, GENERAL & INTERNAL | bsangro@unav.es | ||
|
Suzuki, Yasushi (Suzuki, Y) |
Natl Hosp Org, Sendai Med Ctr, Sendai, Japan |
|
|
[JCR상위 0.2%] Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised double-blind, placebo-controlled study | SCIE | 0.2 | CLINICAL NEUROLOGY | sramcha4@its.jnj.com | ||
|
Thungappa, Satheesh Chiradoni (Thungappa, SC) |
HCG Oncol, Dept Med Oncol, Bangalore, India |
|
|
[JCR상위 0.2%] Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study | SCIE | 0.2 | MEDICINE, GENERAL & INTERNAL | bsangro@unav.es | ||
|
Udoye, Stephanie, I (Udoye, S) |
AstraZeneca, Global Med Dev, Gaithersburg, MD USA |
|
|
[JCR상위 0.2%] Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study | SCIE | 0.2 | MEDICINE, GENERAL & INTERNAL | bsangro@unav.es |
페이지 이동: